Floatz logo

Daunorubicin

Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Princess Maxima Center for Pediatric OncologyPhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
Joanna Yi
Phase 3BBB
THIOGUANINE ANHYDROUS
Grupo Argentino de Tratamiento de la Leucemia Aguda
Phase 3BB
ASPARAGINASE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB

View all 9 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →